Ignite Creation Date:
2025-12-25 @ 1:09 AM
Ignite Modification Date:
2025-12-25 @ 11:20 PM
Study NCT ID:
NCT01238393
Status:
COMPLETED
Last Update Posted:
2016-01-13
First Post:
2010-11-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Treatment of Epiretinal Membranes With Ranibizumab
Sponsor:
Queen's University
Organization:
Study Overview
Official Title:
A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LERM
Brief Summary:
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: